Connect With Us:
- Prova Education Series
- The GI Health Initiative
- From Guideline to Practice: Managing Challenging Cases in Primary Care
- Acute Coronary Syndrome: Bridging the Gaps in Care
- Getting the Red Out: Conjunctivitis and Ocular-nasal Allergies
- Project Oncology
- Clinician's Commentary
- Diabetes: Optimal Glycemic Control and Preventing Complications
- Assessing and Managing Chronic Pain in Primary Care: Applying Evidence to Clinicial Practice
- Best Practices in the Ongoing Management of Patients with Hemophilia
- Prevention of Pneumococcal Disease in Children: Optimizing Vaccine Strategies
- Preterm and Low Birth Weight Infant Nutrition
- Genetic Profiling in Early-Stage Breast Cancer and Beyond
- Medical Resources and References
Genetic Profiling in Early-Stage Breast Cancer and Beyond
This curriculum is designed to improve the management of early-stage breast cancer. The focus is to 1) improve physician decision-making when incorporating treatment algorithms into their clinical practice; 2) evaluate the “value propositions” for genomic/biomarker assays when making treatment decisions; and 3) identify improved treatment options for women with triple negative disease to offer them better outcomes for this difficult to treat subset of early-stage breast cancer.
SATELLITE RADIO BROADCASTS
Two 15-minute radio shows in a question and answer format.
• Broadcasts on XM 167 over 30 times from September 2010 to March 2011
• Post-test available online for credit
You can listen online too!
Genetic Profiling in Early-Stage Breast Cancer, Part 1 of 2
This program is no longer available for CME credits.
Genetic Profiling in Early-Stage Breast Cancer, Part 2 of 2
Overall Educational Purpose
This curriculum is designed to improve the management of early-stage breast cancer. The multi-platform design immerses learners in didactic education and case-based vignettes to help raise physician competence and improve patient outcomes.
Three areas of critical practice improvement include:
The recent St. Gallen treatment decision recommendations for systemic adjuvant therapy of early-stage breast cancer has left oncologists and supporting healthcare professionals with insufficient means to clearly make evidence-based comparisons with existing treatment algorithms within their own clinical practice.
Lack of clarity of the value of genomic/biomarker assays in early-stage breast cancer has left oncologists and supporting healthcare professionals inadequately prepared to assess their “value propositions” when considering treatment decisions for women with early-stage breast cancer.
Estimates are that 10% to 17% of women developing breast cancer will have triple negative disease that is not yet fully served by current attempts to link treatment with tumor profile/gene micro-arrays. Oncologists and supporting healthcare professionals, nationally and at the community level, need forums to engage in critical discussions to expand treatment options for these patients.
Prova Education brings you active learning that includes strategies to apply what you have learned in your clinical practice.
This course is designed to meet the Continuing Medical Education needs of oncologists.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Prova Education and The University of Michigan. The University of Michigan is accredited by the ACCME to provide continuing medical education for physicians.
Samuel M. Silver, MD, PhD
University of Michigan
This activity is supported by an independent educational grant from Pfizer, Inc.